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Abstract 
Background: Duchenne muscular dystrophy is a highly complex multi-system disease caused by primary abnormali-
ties in the membrane cytoskeletal protein dystrophin. Besides progressive skeletal muscle degeneration, this neuro-
muscular disorder is also associated with pathophysiological perturbations in many other organs including the liver. 
To determine potential proteome-wide alterations in liver tissue, we have used a comparative and mass spectrome-
try-based approach to study the dystrophic mdx-4cv mouse model of dystrophinopathy.
Methods: The comparative proteomic profiling of mdx-4cv versus wild type liver extracts was carried out with an 
Orbitrap Fusion Tribrid mass spectrometer. The distribution of identified liver proteins within protein families and 
potential protein interaction patterns were analysed by systems bioinformatics. Key findings on fatty acid binding pro-
teins were confirmed by immunoblot analysis and immunofluorescence microscopy.
Results: The proteomic analysis revealed changes in a variety of protein families, affecting especially fatty acid, carbo-
hydrate and amino acid metabolism, biotransformation, the cellular stress response and ion handling in the mdx-4cv 
liver. Drastically increased protein species were identified as fatty acid binding protein FABP5, ferritin and calumenin. 
Decreased liver proteins included phosphoglycerate kinase, apolipoprotein and perilipin. The drastic change in FABP5 
was independently verified by immunoblotting and immunofluorescence microscopy.
Conclusions: The proteomic results presented here indicate that the intricate and multifaceted pathogenesis of the 
mdx-4cv model of dystrophinopathy is associated with secondary alterations in the liver affecting especially fatty acid 
transportation. Since FABP5 levels were also shown to be elevated in serum from dystrophic mice, this protein might 
be a useful indicator for monitoring liver changes in X-linked muscular dystrophy.
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Background
The X-linked recessively inherited disorder Duchenne 
muscular dystrophy is primarily a monogenetic disease 
of the skeletal musculature [1]. The almost complete 
loss of the membrane cytoskeletal protein dystrophin 
triggers a complex pathogenesis in voluntary muscles 
that is characterized by highly progressive fibre degen-
eration, abnormal calcium homeostasis, fatty tissue 
replacement, reactive myofibrosis and sterile inflamma-
tion [2–4]. However, besides skeletal muscle wasting, 
patients afflicted with dystrophinopathy also exhibit a 
multitude of secondary alterations in the body, includ-
ing respiratory insufficiency, cardiomyopathy, renal and 
urinary tract dysfunction, impaired bone metabolism, 
growth retardation, contractures of tendons, scoliosis 
and gastrointestinal symptoms [5–8], as well as non-
progressive cognitive deficiencies in a subset of patients 
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[9]. In addition, the pathological survey of general organ 
changes in Duchenne patients revealed in most cases 
a marked atrophy of the liver, whereby liver shrinkage 
increased with patient age [10].
Liver atrophy was shown to occur concurrently with 
loss of skeletal muscle mass [10, 11] and liver changes 
were reported to be linked to heart failure in older Duch-
enne patients [12]. Muscular dystrophy was also shown 
to be associated with an increased susceptibility to drug-
induced hepatotoxicity [13, 14]. An interesting connec-
tion between dystrophic skeletal muscles and abnormal 
liver function is related to altered levels of the amino acid 
taurine. Physiological levels of taurine are crucial for the 
normal functioning of skeletal muscles and are related 
to the facilitation of excitation–contraction coupling, 
the modification of intracellular calcium homeosta-
sis, membrane stabilization, the support of anti-oxidant 
defence mechanisms and the osmo-regulation of cel-
lular volume [15]. Deficiency of taurine in dystrophic 
mdx mice was shown to be associated with perturba-
tions in taurine transport and altered metabolism in the 
liver [16]. Thus, the dystrophic phenotype does not only 
feature impaired taurine metabolism in the skeletal mus-
culature, but is also characterized by pathophysiological 
alterations of taurine handling in the liver, which can be 
rectified by increasing dietary taurine causing improved 
contractile strength [17]. This positive effect of taurine is 
probably mediated via anti-inflammatory, anti-oxidant 
and cyto-protective mechanisms [18]. Another interest-
ing liver-related abnormality in the mdx mouse model 
of dystrophinopathy is decreased liver glycogen levels 
and hyperglycemia [19], which agrees with a mild glu-
cose intolerance observed in Duchenne patients [20, 21]. 
Based on these findings, it was of interest to investigate 
whether the dystrophic phenotype is associated with pro-
teome-wide changes in liver tissue.
Mass spectrometry-based proteomics has previously 
been used to study a variety of tissues and organs from 
dystrophic animal models, as summarized in several 
recent review articles [22–24]. The proteomic profil-
ing of the mdx-4cv mouse model of Duchenne muscular 
dystrophy, which is characterized by a low frequency of 
revertant fibres [25–27], has established considerable 
changes in the dystrophin-deficient skeletal musculature, 
heart, brain and serum. Distinct alterations were shown 
to occur in proteins involved in the maintenance of the 
cytoskeletal network, the basal lamina and associated 
extracellular matrix, the regulation of ion homeostasis 
and excitation–contraction coupling, energy metabolism 
and the cellular stress response in various tissues from 
dystrophic animals [28–34]. In analogy, the comparative 
screening of crude liver extracts from mdx-4cv mice out-
lined in this report has shown distinct proteome-wide 
changes in a variety of enzymes, metabolite transporters, 
ion binding proteins, signalling molecules and structural 
proteins. Muscular dystrophy-related perturbations were 
identified to affect especially metabolic pathways in the 
liver, whereby the most drastically increased protein was 
identified as the FABP5 isoform of fatty acid binding pro-
tein and the most decreased protein as phosphoglycerate 
kinase isoform PGK1.
Methods
Materials
For the comparative proteomic analysis of liver tissue 
from wild type versus dystrophic mdx-4cv mice, a variety 
of general analytical grade reagents and materials were 
obtained from GE Healthcare (Little Chalfont, Bucking-
hamshire, UK), Bio-Rad Laboratories (Hemel-Hemp-
stead, Hertfordshire, UK) and Sigma Chemical Company 
(Dorset, UK). National Diagnostics (Atlanta, GA, USA) 
supplied ultrapure acrylamide stock solutions. Sequenc-
ing grade-modified trypsin, Lys-C and Protease Max 
Surfactant Trypsin Enhancer were purchased from Pro-
mega (Madison, WI, USA) and Whatman nitrocellulose 
transfer membranes came from Invitrogen (Carlsbad, 
CA, USA). The chemiluminescence substrate and pro-
tease inhibitors were obtained from Roche Diagnostics 
(Mannheim, Germany). Primary antibodies were from 
Abcam, Cambridge, UK (antibodies ab129203 to fatty 
acid binding protein FABP-1; ab69090 to ferritin light 
chain; ab14734 to the voltage-dependent anion channel 
VDAC-1; ab85366 to carbonic anhydrase isoform CA3; 
and ab2413 to fibronectin), Novus Biologicals, Littleton, 
CO, USA (NBP2-15492 to asporin; and NBP1-80671 to 
the mitochondrial outer membrane protein transloca-
tion pore subunit TOM22), Leica Biosystems, Wetzlar, 
Germany (antibody NCL-DYS1 [clone Dy8/6C5] to dys-
trophin) and Cell Signaling Technology, Leiden, Neth-
erlands (antibody 39926T to fatty acid binding protein 
FABP5). Chemicon International (Temecula, CA, USA) 
provided peroxidase-conjugated secondary antibod-
ies. For immunofluorescence microscopy, normal goat 
serum, goat anti-rabbit Alexa Fluor 488 and goat anti-
mouse IgG RRX (Rhodamine Red-X) were purchased 
from Molecular Probes, Life Technologies (Darmstadt, 
Germany) and Jackson ImmunoResearch (West Grove, 
PA, USA), respectively. The embedding medium Fluoro-
mount G was from Southern Biotech (Birmingham, AL, 
USA).
Dystrophic mdx‑4cv mouse model of Duchenne muscular 
dystrophy
The mdx-4cv mouse model is one of four chemi-
cal variants of the mdx mouse [27], generated on the 
C57/BL6 background by chemical mutagenesis using 
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N-ethyl-nitrosourea [35]. The resulting mutation at base 
7916 in exon 53 of the dystrophin gene introduces a pre-
mature stop codon, thus abrogating dystrophin synthe-
sis. For the identification of global alterations in the liver 
proteome of dystrophic mice, whole liver samples from 
6-month-old control C57/BL6 mice and age-matched 
mdx-4cv mice were obtained from the Bioresource Unit 
of the University of Bonn [29]. Mice were kept under 
standard conditions and all procedures adhered to Ger-
man legislation on the use of animals in experimental 
research. The animals were sacrificed by cervical disloca-
tion and livers were carefully dissected and quick-frozen 
in liquid nitrogen. Samples were transported to May-
nooth University in accordance with the Department of 
Agriculture (animal by-product register number 2016/16 
to the Department of Biology, National University of Ire-
land, Maynooth) on dry ice and stored at − 80 °C prior to 
analysis.
Preparation of liver homogenates from wild type 
and dystrophic mice
For the preparation of crude extracts, 100  mg of liver 
tissue from 6-month-old mdx-4cv mice (n = 4) and age-
matched wild type mice (n = 4) was finely chopped and 
homogenised in 10 volumes of lysis buffer (6  M urea, 
2  M thiourea, supplemented with a protease inhibitor 
cocktail [30]), using a hand-held IKA T10 Basic Homog-
eniser (IKA Labortechnik, Staufen, Germany). Homoge-
nates were kept on ice for 1.5  h and were subsequently 
centrifuged at 14,000×g for 20 min at 4 °C [36]. The pro-
tein-containing supernatant was removed and used for 
comparative proteomic analysis.
Sample preparation for label‑free liquid chromatography 
mass spectrometry
Liver homogenates were treated using the Ready Prep 2D 
clean up kit from BioRad Laboratories, and re-suspended 
in label-free solubilisation buffer (6 M urea, 2 M thiourea, 
10 mM Tris, pH 8.0 in LC–MS grade water). The protein 
concentrations were determined using the Bradford assay 
system [37] and sample volumes were then equalised 
with label-free solubilisation buffer. For mass spectro-
metric analysis, 10  µg of liver homogenate was reduced 
with 10 mM dithiothreitol for 30 min at room tempera-
ture, and alkylated with 25 mM iodoacetamide in 50 mM 
ammonium bicarbonate for 20 min at room temperature 
in the dark. A further 10  mM dithiothreitol was added 
and samples were incubated for 15 min at room tempera-
ture in the dark, to quench any unreacted iodoacetamide 
[38]. Protein samples were first digested with sequenc-
ing grade Lys-C at a ratio of 1:100 (protease:protein) and 
incubated at 37 °C for 4 h. Samples were diluted with four 
times the initial sample volume with 50 mM ammonium 
bicarbonate, and 1  μl of a 1% w/v solution of Protease 
Max Surfactant Trypsin Enhancer was added [39], fol-
lowed by digestion with sequencing grade-modified 
trypsin at a ratio of 1:25 (protease:protein) overnight at 
37 °C. Proteolytic digestion was halted by the addition of 
2% trifluoroacetic acid (TFA) in 20% acetonitrile (ACN) 
(3:1 (v/v) dilution). The peptides were purified using 
Pierce C18 spin columns from Thermo Fisher Scientific 
(Dublin, Ireland), dried through vacuum centrifugation 
and re-suspended in an appropriate volume of loading 
buffer (2% ACN, 0.05% TFA in LC–MS grade water). 
Peptide suspensions were vortexed, sonicated, and cen-
trifuged briefly at 14,000×g before being transferred to 
mass spectrometry vials [31].
Label‑free liquid chromatography mass spectrometry
Reverse-phased capillary high pressure liquid chroma-
tography was carried out using the UltiMate 3000 nano 
system (Thermo Scientific) coupled directly in-line 
with the Thermo Orbitrap Fusion Tribrid Mass Spec-
trometer (Thermo Scientific). The digested samples 
were loaded onto the trapping column (PepMap100, 
C18, 300  μm × 5  mm) at a flow rate of 25  μl/min with 
2% (v/v) ACN, 0.1% (v/v) TFA for 3  min before being 
resolved onto an analytical column (Easy-Spray C18 
75 μm × 500 mm, 2 μm bead diameter column). Peptides 
were eluted using the following binary gradient: solvent 
A (0.1% (v/v) formic acid in LC–MS grade water) and 
2–27.5% solvent B (80% (v/v) ACN, 0.08% (v/v) formic 
acid in LC–MS grade water) for 110  min at a flow rate 
of 300 nl/min. For peptide ionization, a voltage of 1.9 kV 
was applied and a capillary temperature of 320  °C was 
used. Data-dependent acquisition with full scans in the 
375–1500  m/z range was performed using an Orbitrap 
mass analyser with a resolution of 120,000 (at m/z 200), 
a targeted automatic gain control (AGC) value of 4E+05 
and a maximum injection time of 50  ms. The number 
of selected precursor ions for fragmentation was deter-
mined by the top-speed acquisition algorithm. Selected 
precursor ions were isolated in the Quadrupole instru-
ment with an isolation width of 1.6 Da. Peptides with a 
charge state of 2+ to 6+ were analysed and a dynamic 
exclusion was applied after 60  s. Precursor ions were 
fragmented using higher energy collision-induced disso-
ciation (HCD) with a normalized collision energy of 28%, 
and resulting MS/MS ions were measured in the linear 
ion trap. The typical MS/MS scan conditions were as fol-
lows: a targeted AGC value of 2E+04 and a maximum fill 
time of 35 ms.
Protein profiling by label‑free LC–MS/MS
Progenesis QI for Proteomics software (version 3.1; Non-
Linear Dynamics, a Waters company, Newcastle upon 
Page 4 of 17Murphy et al. Clin Proteom           (2018) 15:34 
Tyne, UK) was used for the quantitative analysis of liver 
homogenates from wild type versus mdx-4cv mice. To 
account for potential drifts in retention time, a refer-
ence run was selected and all other runs were aligned to 
this run. The following settings were used to filter pep-
tide features: (1) peptide features with ANOVA ≤ 0.05 
between experimental groups, and (2) mass peaks with 
charge states from + 1 to + 5 and (3) greater than one 
isotope per peptide [31]. A Mascot generic file (mgf) 
was generated from all exported MS/MS spectra, which 
was used for peptide and protein identification via Pro-
teome Discoverer 2.1 (Thermo Scientific) using Sequest 
HT against the UniProtKB-SwissProt Mus musculus 
database. The following search parameters were used: (1) 
peptide mass tolerance set to 10 ppm, (2) MS/MS mass 
tolerance set to 0.6 Da, (3) up to two missed cleavages, (4) 
carbamidomethylation set as a fixed modification and (v) 
methionine oxidation set as a variable modification. For 
re-importation back into Progenesis LC–MS software 
as a PepXML file only highly confident peptides with a 
FDR of ≤ 0.01 as determined by Percolator validation in 
Proteome Discoverer were allowed [40]. The following 
criteria were applied to assign proteins as positively iden-
tified: (1) an ANOVA score between experimental groups 
of ≤ 0.05, (2) proteins with ≥ 2 unique peptides matched 
and (3) a fold change ≥ 1.5. A heat map illustrating pro-
tein abundances for statistically significant and differ-
entially abundant proteins was designed using Perseus 
software version 1.6.2.1. The normalised abundance val-
ues of differentially abundant proteins were determined 
using Progenesis QI for Proteomics and were loaded as 
a txt file into Perseus and the data was log2 transformed. 
Hierarchical clustering was then performed on Z-score 
normalised intensity values by clustering both samples 
and proteins using Euclidean distance and average link-
age. The freely available software packages PANTHER 
[41] and STRING [42] were used to identify protein 
class and characterise potential protein interactions, 
respectively.
Comparative immunoblot analysis
Comparative immunoblotting was used as an orthogo-
nal method for the independent verification of interest-
ing proteins with a differential expression pattern in the 
liver of the mdx-4cv mouse model of Duchenne muscular 
dystrophy. Liver homogenates for immunoblot analysis 
were prepared in 2 × standard Laemmli-type buffer for 
one-dimensional sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) [43], heated at 97  °C 
for 7  min and loaded onto hand-cast 10% SDS-PAGE 
gels. Proteins were transferred to nitrocellulose mem-
branes, blocked in a milk protein solution (2.5% (w/v) 
fat-free milk powder in 10% phosphate-buffered saline) 
and incubated overnight in appropriately diluted primary 
antibody. Following a number of washing steps, mem-
branes were incubated with peroxidase-conjugated sec-
ondary antibodies, and immuno-decorated protein bands 
visualized with the help of the enhanced chemilumines-
cence technique [33]. Densitometric scanning and statis-
tical analysis of immunoblots was performed using a HP 
PSC-2355 scanner and ImageJ software (NIH, Bethesda, 
MD, USA) along with Graph-Pad Prism software (San 
Diego, CA, USA), in which statistical significance was 
based on a p value ≤ 0.05.
Comparative histology and immunofluorescence 
microscopy
In order to establish the loss of the skeletal muscle dys-
trophin isoform Dp427-M in the mdx-4cv mouse model 
of dystrophinopathy and correlate it to potential changes 
in the liver, histological haematoxylin and eosin staining, 
as well as immunofluorescence microscopy were car-
ried out by standardized methodology. Freshly dissected 
liver and muscle specimens from 6-month-old wild type 
and mdx-4cv mice were quick-frozen in liquid nitrogen-
cooled isopentane and 10  µm sections cut in a cryostat 
[29]. For dystrophin immuno-staining, unfixed cryosec-
tions were boiled in phosphate-buffered saline for 5 min 
as previously described in detail [44]. For FABP5 stain-
ing, sections were fixed in a 1:1 (v/v) mixture of metha-
nol and acetone for 10 min at room temperature and then 
blocked with 1:20 diluted normal goat serum for 30 min 
at room temperature. Primary antibodies to dystrophin 
and FABP5 were diluted appropriately in phosphate-
buffered saline for overnight incubation at 4  °C. Tissue 
specimens were carefully washed and then incubated 
with fluorescently-labelled secondary antibodies, using 
either 1:200 diluted anti-rabbit Alexa Fluor 488 antibody 
or 1:200 diluted anti-mouse RRX antibody for 45  min 
at room temperature. Nuclei were counter-stained with 
1 μg/ml bis-benzimide Hoechst 33342. Antibody-labelled 
liver and muscle tissue sections were embedded in Fluo-
romount G medium and viewed under a Zeiss Axioskop 
2 epifluorescence microscope equipped with a digital 
Zeiss AxioCam HRc camera (Carl Zeiss Jena GmbH, 
Jena, Germany). For Sudan Black staining, fresh tissue 
sections were fixed in 10% formalin, washed under tap 
water, rinsed with distilled water and then exposed twice 
for 5  min to propylene glycol. Incubation with Sudan 
Black B (0.7 g dye in 100 ml propylene glycol) was carried 
out for 7  min with agitation, followed by 3  min in 85% 
propylene glycol, rinsing with distilled water, washing 
with tap water, another rinsing step with distilled water 
and finally mounting in an aqueous mounting media of 
glycerin jelly.
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Results
Proteomic profiling of crude extracts from mouse liver
For the comparative proteomic profiling of liver tissue 
from wild type versus the dystrophic mdx-4cv model of 
Duchenne muscular dystrophy, total protein extracts 
were analysed by mass spectrometry. The pathophysi-
ological complexity of dystrophinopathy and the bioana-
lytical approach used to evaluate proteome-wide changes 
in liver tissue is outlined in the flow chart of Fig.  1. In 
the wild type, the multi consensus analysis recognized a 
total of 2536 protein species, which were identified from 
a total of 18,283 peptides and 16,976 unique peptides. Of 
the total number of liver-associated proteomic hits from 
wild type mouse, 1607 proteins were identified by a mini-
mum of two unique peptides. The analysis of the multi 
consensus data of the dystrophic mdx-4cv model recog-
nized a total of 2463 proteins, which were identified from 
a total of 18,543 total peptides and 17,069 unique pep-
tides. Of the total number of liver-associated proteomic 
hits from the mdx-4cv mouse model, 1618 proteins were 
identified by a minimum of two unique peptides.
Since the below outlined proteomic findings suggest 
considerable perturbations of fatty acid transporta-
tion and lipid metabolism, it was of interest to confirm 
the presence of key transporters and enzymes of lipid 
metabolism in this proteomic screening study. Important 
metabolic proteins were identified with high confidence 
in normal liver tissue including markers of (1) fatty acid 
transportation, including the main liver-specific fatty 
acid binding protein isoform FABP1 (L-FABP; P12710), 
as well as the intestinal isoform FABP2 (I-FABP,: P55050), 
the adipocyte isoform FABP4 (A-FABP; P04117) and 
the epidermal isoform FABP5 (E-FABP; Q05816), (2) 
enzymes of malonyl-CoA metabolism, such as acetyl-
CoA carboxylase isoforms ACC1 (Q5SWU9) and ACC2 
(E9Q4Z2) and fatty acid synthase (P19096), (3) acetyl-
CoA transfer proteins, including the mitochondrial 
ACAT1 (Q8QZT1) and cytosolic ACAT2 (Q8CAY6) 
Proteomic profiling of mdx-4cv liver tissue
wt
LIVER
Immunoblot
analysis
Immunofluorescence
microscopy
Liver tissue homogenate
Homogenisation
Protein-containing supernatant 
mdx-4cv
LIVER
n=4 n=4
20’ 14,000g
90’ Incubation on ice
Trypsin digestion
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Comparative proteomic profiling
Alkylation
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Fig. 1 Overview of the complex multi-system pathophysiology of dystrophinopathy and proteomic workflow to analyse the mdx-4cv liver. 
Duchenne muscular dystrophy is caused by primary abnormalities in dystrophin and triggers progressive skeletal muscle wasting, cardio-respiratory 
abnormalities and cognitive impairments. In addition, X-linked muscular dystrophy is also characterized by secondary effects on a variety of organ 
systems including the liver. Proteome-wide changes in liver tissue were determined by comparative proteomics using the dystrophic mdx-4cv 
mouse model of Duchenne muscular dystrophy. Results obtained by mass spectrometry using an Orbitrap Fusion Tribrid apparatus were analysed 
by systems bioinformatics, and key findings were confirmed by verification studies employing immunoblotting and immunofluorescence 
microscopy
Page 6 of 17Murphy et al. Clin Proteom           (2018) 15:34 
isoforms of acetyl-CoA acetyltransferase and liver carni-
tine O-palmitoyl-transferase CPTA1 (P97742), (4) pro-
teins involved in fatty acid oxidation, including various 
mitochondrial short, branched, medium, long and very 
long chain specific acyl-CoA dehydrogenases (P51174, 
Q8K370, Q8JZN5, P45952, Q07417, P50544, Q9DBL1, 
Q80XL6) and 3-hydroxyacyl-CoA dehydrogenase 
(O08756), and (5) enzymes of ketone body metabolism, 
including the cytoplasmic HMGCS1 isoform (Q8JZK9) 
and mitochondrial HMGCS2 isoform (P54869) of 
hydroxyl-methylglutaryl-CoA synthase.
Proteomic profiling of liver tissue from the dystrophic 
mdx‑4cv model of dystrophinopathy
The comparative mass spectrometric analysis of wild 
type versus mdx-4cv liver extracts identified a total of 96 
proteins with a significant change in abundance. Of these 
liver-associated protein species, 44 proteins were found 
to be increased (Table 1) and 52 proteins were shown to 
be decreased (Table  2) in their concentration. The pro-
tein confidence score listed in the tables is the combined 
score of the peptides identified by SEQUEST. There-
fore, if a protein is identified by 3 peptides, the Progen-
esis program adds up the three XCorr scores defined by 
SEQUEST and uses these values as a confidence score for 
the protein result. The listings of proteomic hits included 
37 liver proteins with an altered expression level above 
2-fold. A heat map is shown in Fig.  2 that outlines the 
clustering of significantly increased versus decreased 
proteins in mdx-4cv liver tissue, as compared to control 
tissues. The most drastically increased proteins, which 
did not exhibit differential effects in a closely related iso-
form, were identified as the FABP5 isoform of fatty acid-
binding protein, the calcium binding protein calumenin, 
triokinase, aldolase and epiplakin, as well as the light and 
heavy chains of the iron binding protein ferritin (Table 1). 
In contrast, the most reduced proteins, which did not 
exhibit differential effects in a closely related isoform, 
were shown to be the glycolytic enzyme phosphoglycer-
ate kinase PGK1, apolipoprotein A-II, galectin-1, fatty 
aldehyde dehydrogenase, cysteine sulfinic acid decarbox-
ylase, acyl-coenzyme A thioesterase 1 and mitochondrial 
ornithine aminotransferase, as well as the modulators of 
lipid metabolism perilipin-2 and perilipin-3 (Table 2). A 
few isoforms of related protein species showed differen-
tial changes in the mdx-4cv liver, including cytochrome 
P450-2C29/P450-2C54 versus P450-3A11, Ig alpha chain 
C region versus gamma-2B chain C region, and glu-
tathione S-transferase P1 versus A1.
Bioinformatics analysis of global protein changes 
in the mdx‑4cv liver
The proteomic data sets from the comparative analysis 
of liver tissue from wild type versus mdx-4cv mice were 
analysed by standard bioinformatics software programs, 
i.e. the PANTHER database of protein families and the 
STRING database of protein interactions that include 
both direct physical and indirect functional protein asso-
ciations, in order to group the identified liver-associated 
proteins based on their protein class and to evaluate 
potential protein interaction patterns. As outlined in the 
PANTHER analysis graph of Fig. 3, the proteomic survey 
of mdx-4cv liver extracts revealed considerable altera-
tions in a variety of enzymes belonging to the classes of 
hydrolases, oxidoreductases and transferases, as well as 
proteins involved in membrane trafficking, cell adhesion, 
cytoskeletal maintenance, cellular defence and immu-
nity (Tables  1, 2). Potential interaction maps of altered 
proteins were established by STRING analyses, which 
indicate a few protein hubs of potential importance for 
explaining the perturbed protein expression patterns in 
the mdx-4cv liver. Protein clustering of increased pro-
teins appears to occur at the level of certain isoforms 
of cytochrome P450 and glutathione transferase, pro-
tein disulfide-isomerase, peroxiredoxin and heat shock 
protein HspA5, ferritin light and heavy chains, aldo-
lase isoforms, vimentin, plectin and myosin-9, and the 
epidermal growth factor receptor, calumenin and fatty 
acid binding protein FABP5 (Fig.  4). This is indicative 
of increased biotransformation, molecular chaperoning 
and cellular signalling. Protein hubs with components of 
decreased abundance centre around epoxide hydrolase 
and glutathione transferase isoforms, sulphide oxidase, 
fatty aldehyde dehydrogenase, serine racemase and dehy-
dratase, glycine methyltransferase, apolipoproteins, and 
phosphoglycerate kinase PGK1 (Fig. 5).
Drastic increase of fatty acid binding protein FABP5 
in the mdx‑4cv liver
A major finding of this study was the drastic increase 
in FABP5, which was identified by 3 unique peptides. 
The sequence alignment of the protein family of FABPs 
in Mus musculus is shown in Fig.  6. FABP isoforms 
1–9 and 12 represent the proteins located in the liver 
(L-FABP), intestine (I-FABP), heart (H-FABP), adi-
pocytes (A-FABP), epidermal tissue (E-FABP), ileum 
(Il-FABP), brain (B-FABP), myelin (M-FABP) and tes-
tis (T-FABP), respectively. The mass spectrometric 
identification shows that the identifying peptides are 
unique to isoform FABP5 (Fig.  6). The epidermal iso-
form FABP5, also known as keratinocyte-type FABP or 
psoriasis-associated-FABP, has been found in a great 
variety of organs, tissues and cell types including skin, 
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Table 1 Proteomic identification of  liver proteins with  an  increased abundance in  the  mdx-4cv model 
of dystrophinopathy
Accession Gene name Description Unique 
peptides
Confidence score Anova (p) Max fold change
Q05816 Fabp5 Fatty acid-binding protein, epidermal 3 10.5609 0.00875 19.78
Q64458 Cyp2c29 Cytochrome P450 2C29 2 6.5311 0.01688 3.75
P01878 N/A Ig alpha chain C region 2 9.0393 0.00267 3.27
P29391 Ftl1 Ferritin light chain 1 8 23.6657 0.02194 3.00
O35887 Calu Calumenin 2 7.26614 0.02929 2.99
P09528 Fth1 Ferritin heavy chain 4 25.8182 0.00734 2.81
Q8VC30 Tkfc Triokinase/FMN cyclase 2 6.2330 0.02067 2.66
P05063 Aldoc Fructose-bisphosphate aldolase C 3 7.7044 0.00265 2.40
Q8K182 C8a Complement component C8 alpha chain 3 12.0831 0.01038 2.24
Q8R0W0 Eppk1 Epiplakin 5 20.9671 0.00183 2.18
Q61490 Alcam CD166 antigen 2 5.2107 0.00250 2.17
Q01279 Egfr Epidermal growth factor receptor 5 18.7714 0.01288 2.15
Q6XVG2 Cyp2c54 Cytochrome P450 2C54 3 11.5034 0.00478 2.11
P28666 Mug2 Murinoglobulin-2 3 8.3401 0.01112 2.02
O08807 Prdx4 Peroxiredoxin-4 5 22.4464 0.00022 1.95
Q9WVJ3 Cpq Carboxypeptidase Q 2 5.6121 0.02628 1.92
Q8CFX1 H6pd GDH/6PGL endoplasmic bifunctional protein 4 12.9820 0.00227 1.90
Q6P5E4 Uggt1 UDP-glucose:glycolprotein glucosyltransferase 1 2 7.1692 0.00337 1.89
Q3UPL0 Sec31a Protein transport protein Sec31A 2 7.6000 0.00183 1.88
Q60866 Pter Phosphotriesterase-related protein 4 14.1754 0.01619 1.87
P17563 Selenbp1 Selenium-binding protein 1 14 61.3323 0.00128 1.82
P19157 Gstp1 Glutathione S-transferase P 1 5 19.3699 0.00183 1.79
P55302 Lrpap1 Alpha-2-macroglobulin receptor-associated protein 3 9.5635 0.01538 1.76
O08600 Endog Endonuclease G, mitochondrial 3 9.6149 0.00536 1.74
Q61694 Hsd3b5 3 beta-hydroxysteroid dehydrogenase type 5 2 7.7579 0.01446 1.73
Q922R8 Pdia6 Protein disulfide-isomerase A6 5 16.2039 0.00687 1.71
Q8BTY1 Kyat1 Kynurenine–oxoglutarate transaminase 1 5 20.5273 0.00447 1.71
Q8VCU1 Ces3b Carboxylesterase 3B 5 15.2176 0.00868 1.71
Q99P27 Pla2g12b Group XIIB secretory phospholipase A2-like protein 2 8.1664 0.02943 1.70
P05064 Aldoa Fructose-bisphosphate aldolase A 7 24.4402 0.00015 1.69
Q9QXS1 Plec Plectin 4 12.2329 0.00367 1.69
Q921X9 Pdia5 Protein disulfide-isomerase A5 5 19.1847 0.00385 1.66
P05784 Krt18 Keratin, type I cytoskeletal 18 3 10.1094 0.02249 1.65
Q9JKR6 Hyou1 Hypoxia up-regulated protein 1 7 26.4824 0.00022 1.64
Q9CPT4 Mydgf Myeloid-derived growth factor 2 6.4866 0.01417 1.62
P52840 Sult1a1 Sulfotransferase 1A1 3 11.3351 0.00914 1.62
P20029 Hspa5 78 kDa glucose-regulated protein 9 32.5662 0.00432 1.61
Q9QZ85 Iigp1 Interferon-inducible GTPase 1 3 9.9380 0.00171 1.60
Q8VDD5 Myh9 Myosin-9 18 69.8377 0.00808 1.58
Q8BL66 Eea1 Early endosome antigen 1 4 15.6173 0.00058 1.56
P20152 Vim Vimentin 4 11.0748 0.00435 1.55
P16675 Ctsa Lysosomal protective protein 2 10.4083 0.00248 1.54
P24369 Ppib Peptidyl-prolyl cis–trans isomerase B 4 13.1642 0.02870 1.53
Q99PL5 Rrbp1 Ribosome-binding protein 1 19 64.9991 0.00166 1.50
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Table 2 Proteomic identification of liver proteins with a decreased abundance in the mdx-4cv model of dystrophinopathy
Accession Gene name Description Unique 
peptides
Confidence score Anova (p) Max fold change
P09411 Pgk1 Phosphoglycerate kinase 1 4 13.9587 2.53E−09 14.97
Q64459 Cyp3a11 Cytochrome P450 3A11 5 17.1715 0.00056 9.53
P09813 Apoa2 Apolipoprotein A-II 2 9.5295 0.00130 6.98
P16045 Lgals1 Galectin-1 2 4.2800 0.00138 6.51
P47740 Aldh3a2 Fatty aldehyde dehydrogenase 7 24.1473 0.00055 6.02
P43883 Plin2 Perilipin-2 4 10.1732 0.02351 5.71
Q9DBE0 Csad Cysteine sulfinic acid decarboxylase 13 41.5240 0.00220 5.63
P13745 Gsta1 Glutathione S-transferase A1 2 4.6699 0.02167 4.22
P01867 Igh-3 Ig gamma-2B chain C region 3 8.7297 0.01044 3.48
O55137 Acot1 Acyl-coenzyme A thioesterase 1 4 17.5564 0.00199 3.39
P29758 Oat Ornithine aminotransferase, mitochondrial 22 74.8421 0.00012 2.79
Q9DBG5 Plin3 Perilipin-3 2 5.2382 0.01285 2.63
Q91VS7 Mgst1 Microsomal glutathione S-transferase 1 4 10.5855 0.00520 2.57
P06801 Me1 NADP-dependent malic enzyme 4 11.4988 0.01467 2.44
Q8VCH0 Acaa1b 3-ketoacyl-CoA thiolase B, peroxisomal 10 39.1412 0.00755 2.37
P22599 Serpina1b Alpha-1-antitrypsin 1-2 3 7.0562 0.00500 2.34
Q9QZX7 Srr Serine racemase 2 6.2347 0.02590 2.24
O54754 Aox1 Aldehyde oxidase 1 2 6.4066 0.00869 2.21
Q8BGT5 Gpt2 Alanine aminotransferase 2 8 26.9779 5.36E−05 2.17
Q8R086 Suox Sulfite oxidase, mitochondrial 13 55.1200 0.00039 2.12
P16015 Ca3 Carbonic anhydrase 3 6 20.1812 0.00752 2.11
Q9D379 Ephx1 Epoxide hydrolase 1 3 8.8219 0.00583 2.11
P07759 Serpina3 k Serine protease inhibitor A3 K 2 8.0261 0.00156 2.04
Q8VBT2 Sds l-serine dehydratase/l-threonine deaminase 3 8.3410 0.04215 1.97
Q9QZD8 Slc25a10 Mitochondrial dicarboxylate carrier 6 22.5548 0.00119 1.94
Q91X83 Mat1a S-adenosyl-methionine synthase isoform 1 7 21.4321 0.01511 1.92
Q9QXX4 Slc25a13 Calcium-binding mitochondrial carrier protein Aralar2 2 8.3671 0.02466 1.87
Q99L20 Gstt3 Glutathione S-transferase theta-3 6 23.9548 0.00840 1.86
Q8CAQ8-5 Immt Isoform 5 of MIC complex subunit Mic60 4 11.5137 0.00397 1.86
Q922B1 Macrod1 O-acetyl-ADP-ribose deacetylase MACROD1 2 6.7757 0.00065 1.86
Q9D7I5 Lhpp Phospholysine phosphohistidine inorganic pyrophos-
phate phosphatase
3 8.5881 0.00382 1.85
Q921H8 Acaa1a 3-ketoacyl-CoA thiolase A, peroxisomal 2 8.07142 0.00063 1.84
Q64176 Ces1e Carboxylesterase 1E 3 12.0204 0.01780 1.79
P61922 Abat 4-aminobutyrate aminotransferase, mitochondrial 7 24.4437 0.00016 1.75
O35490 Bhmt Betaine–homocysteine S-methyltransferase 1 4 13.8152 0.03353 1.73
Q8BUV3 Gphn Gephyrin 2 5.9008 0.01958 1.69
P02088 Hbb-b1 Hemoglobin subunit beta-1 2 7.9579 0.03523 1.67
P13707 Gpd1 Glycerol-3-phosphate dehydrogenase, cytoplasmic 9 30.8543 0.01008 1.63
Q91WG0 Ces2c Acylcarnitine hydrolase 4 12.3891 0.00150 1.63
P15327 Bpgm Bisphospho-glycerate mutase 3 10.8651 0.01946 1.61
P15626 Gstm2 Glutathione S-transferase Mu 2 3 8.9072 0.02081 1.60
Q9D0F9 Pgm1 Phosphogluco-mutase-1 2 7.4358 0.03949 1.60
Q99K51 Pls3 Plastin-3 3 15.7664 0.00796 1.58
Q9QXF8 Gnmt Glycine N-methyltransferase 4 13.7679 0.00466 1.57
P41216 Acsl1 Long-chain-fatty-acid–CoA ligase 1 13 41.6748 0.00427 1.57
Q9DCM0 Ethe1 Persulfide dioxygenase ETHE1, mitochondrial 3 7.8214 7.48E−05 1.56
O35678 Mgll Monoglyceride lipase 3 9.8837 0.00490 1.55
Q9WUZ9 Entpd5 Ectonucleoside triphosphate diphospho-hydrolase 5 2 6.6691 0.00680 1.55
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liver, tongue, mammary glands, brain, stomach, intes-
tine, kidney, lung, heart, skeletal muscle, testis, retina, 
lens, spleen, placenta, adipocytes, macrophages and 
dendritic cells [45]. This agrees with the proteomic 
identification of FABP5 in wild type and mdx-4cv liver.
Immunoblot analysis of fatty acid binding protein FABP5 
in the mdx‑4cv liver
To independently verify the status of the most signifi-
cantly increased liver-associated protein species, as 
determined by comparative proteomics, immunob-
lot analysis and immunofluorescence microscopy was 
carried out with a focus on the FABP5 isoform of fatty 
acid binding protein. The silver-stained gel in Fig.  7 
showed no major changes in the overall protein banding 
pattern between wild type and mdx-4cv liver extracts. 
However, the immunoblotting of FABP isoforms using 
specific antibodies to FABP1 versus FABP5 confirmed 
the significant increase of the FABP-5 (E-FABP) isoform 
in the mdx-4cv liver, but showed no major changes in 
the abundance of the FABP-1 (L-FABP) isoform (Fig. 7). 
The proteomic identification of increased levels of liver-
associated ferritin light chain agreed with a tendency of 
an increased concentration of the iron-binding protein 
as determined by immunoblotting, but these findings 
were not shown to be statistically significant. In addition, 
immunoblotting was used to demonstrate the compara-
ble concentration of a variety of liver-associated marker 
proteins, including the CA3 isoform of carbonic anhy-
drase, the voltage-dependent anion channel VDAC-1; 
the mitochondrial outer membrane protein translocation 
pore subunit TOM22, fibronectin and asporin (Fig. 7).
Immunofluorescence microscopical analysis of mdx‑4cv 
skeletal muscle and liver
To establish the mutant status of the genetic mouse 
model used in this comparative proteomic study of 
the mdx-4cv liver, histological changes in the skeletal 
musculature were assessed by standard haematoxylin/
eosin staining and the deficiency in dystrophin iso-
form Dp427-M was confirmed by immunofluorescence 
microscopy [27]. Figure  8 illustrates that dystrophin 
deficiency is associated with a greater variety in fibre 
diameter in the mdx-4cv gastrocnemius muscle. The 
drastic increase in central nucleation in mdx-4cv mus-
cle fibres was visualized by haematoxylin/eosin staining. 
Sudan Black staining of the mdx-4cv liver showed spe-
cific changes in the cellular composition of hepatocytes, 
indicated by increased levels of blue-black staining pat-
terns that are representative of fat deposition in the liver 
from dystrophic mice (Fig.  8). The immunofluorescence 
microscopical comparison of FABP5 in wild type ver-
sus mdx-4cv liver tissue revealed increased levels in the 
dystrophic model. Although the fluorescent labelling of 
FABP5 is relatively weak, the elevated staining pattern 
in the mdx-4cv liver agreed with the findings from the 
Table 2 (continued)
Accession Gene name Description Unique 
peptides
Confidence score Anova (p) Max fold change
Q9WVL0 Gstz1 Maleylacetoacetate isomerase 2 6.1377 0.00435 1.54
Q8CC88 Vwa8 von Willebrand factor A domain-containing protein 8 11 35.6611 0.00040 1.54
P34928 Apoc1 Apolipoprotein C-I 2 7.9163 0.00828 1.54
O08756 Hsd17b10 3-hydroxyacyl-CoA dehydrogenase 2 3 10.6184 0.00691 1.53
Fig. 2 Heat map of differentially expressed proteins in the mdx-4cv 
liver. Shown is the clustering of significantly increased versus 
decreased proteins in liver tissue from the dystrophic mdx-4cv mouse 
model of Duchenne muscular dystrophy, as compared to control 
tissues. For the identification of proteome-wide changes in the liver, 
protein extracts from whole tissue preparations of 6-month-old 
mdx-4cv mice (n = 4; MDX-4CV 1–4) versus age-matched wild type 
mice (n = 4; WT 1–4) were analysed by mass spectrometry-based 
proteomics
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proteomic survey and the immunoblot analysis of this 
protein isoform.
Discussion
As the largest multi-functional internal organ in the 
body, the liver has a very broad variety of biochemical 
functions, including digestion, nutrient storage, the inte-
gration of key metabolic pathways, the essential detoxi-
fication of xenobiotic substances, protein synthesis and 
immunity [46]. The transcriptome and proteome of 
human liver tissue has been extensively categorised by 
large-scale profiling studies [47–50] and detailed bioin-
formatics databases have been established that specifi-
cally focus on molecular hepatology in health and disease 
[51, 52]. Building on these data banks of liver protein 
expression, including findings from detailed catalogu-
ing studies of the mouse liver proteome [53–55], we have 
used here a comparative proteomic approach to study 
potential changes in liver proteins due to X-linked mus-
cular dystrophy. Drastic changes in the mdx-4cv liver 
were established for protein species involved in fatty acid 
metabolism, metabolite transportation, carbohydrate 
metabolism, amino acid metabolism, protein processing, 
ion handling, biotransformation and the cellular stress 
response. The finding that of all of the mass spectromet-
rically detected proteins only relatively few were identi-
fied as being differentially expressed is most likely due to 
the fact that the mdx-4cv liver is only indirectly affected 
in muscular dystrophy. In contrast to the drastic and pri-
mary effect of the loss of the full-length muscle isoform 
of dystrophin in contractile tissues, non-muscle cells and 
tissues that do not express the full-length dystrophin iso-
form might thus only exhibit relatively few proteome-
wide changes. Instead secondary changes in metabolism 
might represent the main response of the liver to primary 
dystrophin deficiency-induced alterations in skeletal 
muscle, cardiac tissue, the central nervous system and 
the circulatory system.
One of the most intriguing findings of this study is the 
striking increase in fatty acid binding protein FABP5, 
which is indicative of specific changes in the binding of 
long-chain fatty acids and other lipophilic ligands [56], as 
well as alterations in associated cellular signalling events 
[57]. Interestingly, the liver isoform FABP1 was shown 
not to be majorly affected in liver tissue in dystrophi-
nopathy. Of note, a variety of FABP isoforms, including 
FABP1, FABP3 and FABP5, were identified by proteom-
ics in serum from the mdx-4cv mouse [32] and Duch-
enne patients [58–60]. Since the well-characterized FABP 
isoforms 1–9 and 12 have a broad expression pattern in 
many tissues and organs throughout the body [45], it 
is not possible to properly correlate serum changes in 
individual FABP isoforms to specific pathophysiological 
shedding events in particular organs. FABPs belong to 
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Fig. 3 Summary of changed protein classes in liver tissue extracts from the mdx-4cv mouse model of dystrophinopathy. In order to identify the 
clustering of protein classes based on the mass spectrometric analysis of wild type versus mdx-4cv liver (Tables 1, 2), the bioinformatics software 
programme PANTHER [41] was used
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the class of intracellular lipid-binding proteins that are 
primarily involved in the reversible binding of hydropho-
bic ligands and their subcellular trafficking through major 
organellar systems [45]. In addition, individual FABPs 
have also myokine and adipokine functions that regulate 
signalling events in relation to body-wide metabolic con-
trol. The drastic increase of FABP5 in the mdx-4cv liver 
would suggest this protein as a potential biomarker can-
didate of liver dysfunction in X-linked muscular dystro-
phy. However, changes in FABPs were previously shown 
to occur in many common disorders. Dysregulation was 
established for FABP3 in cardiovascular disorders [56, 
61], FABP1, FABP2, FABP4 and FABP5 in non-alcoholic 
fatty liver disease [56, 62] and FABP5 and FABP7 in can-
cer [56, 63, 64]. Although this excludes the dystrophinop-
athy-associated change in liver FABP5 as a robust and 
highly specific biomarker of X-linked muscular dystro-
phy, altered FABP5 levels may nevertheless be useful as 
a general pathophysiological marker in conjunction with 
other disease indicators.
In general, enzymes involved in fatty acid metabo-
lism were differentially affected in the mdx-4cv liver, 
including decreases in apolipoprotein A-II, fatty alde-
hyde dehydrogenase and acyl-coenzyme A thioesterase 
1. Apolipoproteins are essential mediators of lipid bind-
ing and transportation through the lymphatic and circu-
latory systems, but also function as receptor ligands and 
enzyme cofactors. A key component of the detoxification 
pathway of saturated and unsaturated aldehydes, which 
arise from lipid peroxidation, is the fatty aldehyde dehy-
drogenase that converts long-chain aliphatic aldehydes to 
fatty acids. The regulation of intracellular levels of acyl-
CoA and free fatty acids is related to the activity levels of 
acyl-CoA thioesterases, which catalyses the hydrolysis of 
acyl-CoA molecules to coenzyme A and free fatty acids 
[65, 66]. In addition, the essential modulators of lipid 
metabolism, perilipin-2 and perilipin-3, were shown to 
be reduced in the mdx-4cv liver. During lipogenesis in the 
liver, excess energy is stored as triacylglycerol units in the 
form of lipid droplets, and this stored energy is released 
again by hydrolysis in lipolytic pathways [67]. The family 
of cytosolic lipid droplet coat proteins, named perilipin 
PLIN1 to 5, coordinate this process of lipid storage, reac-
tivation and utilization. Pathophysiological imbalances 
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Fig. 4 Overview of potential protein interaction patterns between increased proteins in liver tissue extracts from the mdx-4cv mouse model of 
dystrophinopathy. In order to identify protein interactions, based on both direct physical and indirect functional protein associations, of the mass 
spectrometrically identified proteins from wild type versus mdx-4cv liver (Table 1), the bioinformatics software programme STRING [42] was used
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of lipid droplet homeostasis may trigger lipocytotoxicity 
[68]. Thus, the changed perilipin levels identified in this 
proteomic study suggest that the physiological regula-
tion of lipid accumulation and release of triacylglycerol 
appears to be altered in the liver in muscular dystrophy. 
This may play a role in the overall perturbation of lipid 
metabolism in dystrophinopathy.
The proteomic profile of the mdx-4cv liver showed 
differential changes in the concentration of enzymes 
involved in cellular carbohydrate metabolism, including 
increases in triokinase, which catalyses the phospho-
rylation of both glyceraldehyde and dihydroxyacetone 
[69]. A disturbed regulation of carbohydrate metabo-
lism may be the underlying cause of decreased liver 
glycogen levels [19] and a mild glucose intolerance 
in dystrophinopathy [20, 21]. Opposite concentra-
tion changes were established for two key enzymes 
of glycolysis, i.e. increases in fructose-bisphosphate 
aldolase and decreases in phosphoglycerate kinase. 
Aldolase mediates the reversible reaction that breaks 
down fructose-1,6-biphosphate into dihydroxyacetone 
phosphate and glyceraldehyde-3-phosphate in the 
glycolytic pathway. Phosphoglycerate kinase catalysis 
a crucial ATP-generating transfer reaction in glycolysis 
by forming 3-phosphoglycerate from ADP and 1,3-bis-
phosphoglycerate. During gluconeogenesis, phospho-
glycerate kinase catalyses the reverse reaction, making 
it a key regulator of glucose metabolism [70]. Differen-
tial changes in glycolytic enzymes were also observed 
in dystrophic skeletal muscle and cardiac tissue [29, 33, 
36, 71, 72]. These findings suggest considerable second-
ary and body-wide changes in carbohydrate metabo-
lism due to dystrophin deficiency. However, besides 
their metabolic functions, glycolytic enzymes exhibit a 
multifaceted role in transcriptional regulation, stimula-
tion of cell motility and the regulation of cell death [73]. 
These non-glycolytic functions appear to link metabo-
lism to epigenetic and transcription programs [74] and 
might also be affected in dystrophinopathy.
Besides alterations in key metabolic processes, mass 
spectrometry identified significant increases in two 
essential ion-binding proteins, e.g. calumenin and fer-
ritin. Their elevated levels in the mdx-4cv liver might 
present compensatory mechanisms to counter-act 
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Fig. 5 Overview of potential protein interaction patterns between decreased proteins in liver tissue extracts from the mdx-4cv mouse model of 
dystrophinopathy. In order to identify protein interactions, based on both direct physical and indirect functional protein associations, of the mass 
spectrometrically identified proteins from wild type versus mdx-4cv liver (Table 2), the bioinformatics software programme STRING [42] was used
Page 13 of 17Murphy et al. Clin Proteom           (2018) 15:34 
X-LINKED MUSCULAR DYSTROPHY
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Fig. 6 Overview of the proteomic identification of the fatty acid binding protein FABP5 in liver tissue extracts from the mdx-4cv mouse model of 
dystrophinopathy. Shown is the potential correlation between primary skeletal muscle abnormalities in X-linked muscular dystrophy and secondary 
changes in liver metabolism, as well as an overview of affected biochemical pathways in the mdx-4cv liver as determined by LS-MS/MS analysis. The 
mass spectrometric fingerprint of the most increased protein species in the mdx-4cv liver, FABP5, is shown and a comparative sequence alignment 
with other members of the FABP family to illustrate the uniqueness of the identifying peptide sequence of FABP5
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Fig. 7 Comparative immunoblot analysis of normal wild type versus mdx-4cv liver extracts. Shown is a representative silver-stained SDS-PAGE 
gel and corresponding immunoblots with expanded views of labelling with antibodies to the fatty acid binding protein isoforms FABP1 and 
FABP5, as well as ferritin light chain, carbonic anhydrase isoform CA3, the voltage-dependent anion channel VDAC-1, the mitochondrial outer 
membrane protein translocation pore subunit TOM22, fibronectin and asporin. Lanes 1 and 2 represent total extracts from control wild type (wt) 
liver and mdx-4cv liver, respectively. Molecular mass standards (in kDa) are indicated at the left of the gel image. Graphical representations of the 
immuno-decoration levels of FABP1 and FABP5 are shown (Y-axis: % control): Student’s t test, unpaired; n = 4; *p < 0.05
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abnormal calcium handling and iron toxicity. Calumenin 
is a relatively low-affinity  Ca2+-binding protein, which 
plays a biochemical role in protein folding and sort-
ing mechanisms in the endoplasmic reticulum. In the 
secretory pathway of the endoplasmic reticulum, calu-
menin regulates the activity of the SERCA2a isoform of 
the  Ca2+-pumping ATPase and the ryanodine receptor 
 Ca2+-release channel [75]. Hence, up-regulation of calu-
menin might counter-act disturbed calcium homeostasis 
in the mdx-4cv liver. In analogy, the increased concentra-
tion of the light and heavy chains of liver ferritin might 
act as a cytosolic iron-buffering system in the mdx-4cv 
liver that prevents a detrimental iron imbalance. Both, 
iron deficiency or iron overload may trigger abnormal 
cellular functions [76] and therefore has to be properly 
balanced by abundant intracellular iron-binding proteins 
[77]. The ferritin type of iron-binding proteins seques-
ter and release iron in a highly regulated way and serve 
in most tissues a dual physiological function, which 
provides both a pathway for efficient iron detoxification 
and storage of a cellular iron reserve [78]. Besides the 
liver, ferritin light and heavy chains were previously also 
shown to be drastically increased in dystrophin-deficient 
heart tissue [72] and skeletal muscle [29, 79, 80]. In addi-
tion, urinary ferritin levels are greatly increased in young 
Duchenne patients and are suggested to be functionally 
linked to the renal management of myoglobin iron that 
derived from the disintegration of dystrophic muscles 
[81]. These findings suggest that elevated levels of ferritin 
in the dystrophic phenotype act as a physiological buffer 
against a potential iron overload.
Besides the above discussed alterations in mostly meta-
bolic proteins, including abundant enzymes, transport-
ers and binding proteins, less pronounced changes were 
identified in various markers of cytoskeletal maintenance, 
biotransformation, anti-oxidative mechanisms, protease 
activity, regulation of cellular growth and differentiation, 
and the cellular stress response. Established markers of 
this wide range of processes in the liver are epiplakin, 
cytochrome P450 isoforms, glutathione transferases, per-
oxiredoxin, carboxypeptidase, alpha-1-antitrypsin, epi-
dermal growth factor receptor, galectin, protein disulfide 
wt Liver mdx -4cv Liverwt Muscle mdx-4cv Muscle
H&E H&EH&EH&E
Sudan Black Sudan Black
Dp427 / DAPI Dp427 / DAPI
FABP5 / DAPI FABP5 / DAPI
Fig. 8 Histological and immunofluorescence microscopical analysis of wild type versus mdx-4cv muscle and liver. Shown is the select labelling 
of transverse cryosections from normal wild type (wt) versus mdx-4cv gastrocnemius muscle and liver with haematoxylin/eosin (H&E), as well as 
antibodies to dystrophin isoform Dp427 and the fatty acid binding protein isoform FABP5. Liver sections were also labelled with Sudan Black dye. 
Bars equal 50 μm
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isomerase and molecular chaperones. These complex and 
proteome-wide changes in the mdx-4cv liver suggest gen-
eral perturbations of hepatic function in X-linked muscu-
lar dystrophy. Since increasing dietary taurine was shown 
to increase contractile strength in dystrophinopathy [17], 
it will be interesting to evaluate in future studies whether 
elevated taurine levels trigger an anti-inflammatory, anti-
oxidant and/or cyto-protective response [18] and possi-
bly improve transport and metabolism of this amino acid 
in the liver from dystrophic organisms [16].
Conclusions
Previous studies on liver abnormalities in Duchenne 
muscular dystrophy have established that liver atrophy 
occurs concurrently with skeletal muscle wasting and 
that this secondary pathology may be linked to heart fail-
ure in older patients suffering from dystrophinopathy. 
In addition, an increased susceptibility to drug-induced 
hepatotoxicity is associated with X-linked muscular 
dystrophy. The comparative proteomic study of the dys-
trophic mdx-4cv mouse model of dystrophinopathy 
outlined in this report confirms liver abnormalities and 
identified expression changes in a variety of liver proteins 
due to dystrophin deficiency. The systematic mass spec-
trometric survey of the mdx-4cv liver suggests that liver 
metabolism is perturbed and increased levels of the fatty 
acid binding protein FABP5 appear to be a major patho-
biochemical feature of the dystrophic mdx-4cv pheno-
type. A variety of changes in other metabolic enzymes, 
binding proteins and transporters may present adapta-
tions or compensatory mechanisms to prevent cellular 
complications due to lipocytotoxicity or iron overload in 
an organism that lacks the membrane cytoskeletal pro-
tein dystrophin.
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